ClinicalTrials.gov
ClinicalTrials.gov Menu

Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02589366
Recruitment Status : Terminated
First Posted : October 28, 2015
Last Update Posted : October 15, 2018
Sponsor:
Collaborator:
Cardinal Health 414, LLC
Information provided by (Responsible Party):
Michael McHale, University of California, San Diego

Brief Summary:

Part of standard treatment for endometrial cancer is to remove one or more groups of lymph nodes (lymph node dissection). Lymph nodes are small, bean-shaped organs located within the body throughout the lymphatic system (the tissues and organs involved in immunity, which aids in the fight against infection and cancer).

The purpose of this study is to compare the safety and ability of Lymphoseek and a Vital Blue Dye (tracing agent) to find lymph nodes that may carry cancer from the tumor through the lymphatic system. Lymphoseek will be injected into the tumor on the day before surgery to remove lymph nodes. Vital Blue Dye will be administered during surgery to trace the cancer as well. The surgeon will remove the lymph nodes as part of routine surgery and will keep track of which lymph nodes are identified by Lymphoseek and Vital Blue Dye. These nodes will be sent to another doctor to view them under a microscope and see if the nodes contain cancer cells.

The hypothesis is that Lymphoseek can be used safely and will be at least as effective as blue dye in identifying the lymph nodes that may have cancer cells.


Condition or disease Intervention/treatment Phase
Endometrial Cancer Drug: Lymphoseek plus Vital Blue Dye Phase 1

Detailed Description:

This is an open-label, single center, intra-patient safety and comparison study of Lymphoseek (Technetium Tc 99m Tilmanocept) and vital blue dye for the detection of lymph nodes in patients with endometrial cancer that are undergoing a lymph node dissection as part of their standard medical care.

The day before surgery, patients will have their tumor injected with 50 µg Lymphoseek radiolabeled with 75 megabecquerel (MBq) Tc 99m. Vital signs will be monitored for thirty minutes and then patients will undergo a whole body scan and single photon emission computed tomography/ x-ray computed tomography (SPECT/CT) one to two hours after Lymphoseek injection.

Fourteen to twenty hours after injection of Lymphoseek, patients will have a physical exam and clinical laboratory tests assessed prior to undergoing surgery. Sentinel lymph node identification begins with injection of Vital Blue Dye. Surgical access will be made to the lymphatic basins where nodes are expected to be. Sentinel lymph nodes will be identified by a hand-held gamma counter and/or blue appearance. The threshold criterion for positive "hot" nodes based on radioactivity is a count greater than the quantity of 3 square roots of the mean background count (i.e., standard deviation) added to the mean background count (referred to as the "3σ rule"). Once a lymph node has been identified, in vivo counts should be taken prior to excision. In vivo counts will consist of a set of three 1-second counts over the lymph node. A positive finding (i.e., localization) is a designated "hot" node (described above). Any lymph node count not meeting this threshold criterion will be considered a negative (non-localized) finding. To confirm the in vivo procedure, a set of three 1-second counts will be recorded for the excised lymph nodes. The count of the ex vivo lymph nodes will be compared to the room background counts, and the threshold criterion used to determine a positive finding for the in vivo nodes will be applied to the ex vivo specimens.

A thorough evaluation of the remaining lymphatic basin will be complete when all selected node counts are negative by use of the threshold criterion. The surgeon will continue with visualization and palpation according to local practice to ensure that no grossly positive lymph nodes remain at the site of resection. After identifying the sentinel lymph nodes, standard lymph node dissection will be performed. All removed lymph nodes are sent to pathology for further evaluation. All removed lymph nodes will be sent to pathology and will be confirmed for radioactive status (due to Lymphoseek) and blue appearance (due to vital blue dye. The pathological evaluation of lymph node(s) will include serial sectioning with H&E staining as well as immuno-histochemistry (IHC) stain according to institutional practice.

Patients will return for a routine post-operative follow-up visit 7-14 days after surgery for assessment of adverse events.

The primary objective is safety of Lymphoseek as measured by the incidence of adverse events, changes in laboratory values, vital signs and physical exam findings, and the radiation absorbed dose. Secondary evaluations include (1) the number of lymph nodes detected as "hot" by preoperative imaging (whole body scan and SPECT/CT) and intraoperative gamma detection, and (2) the rate of concordance between Lymphoseek and Vital Blue Dye in the in vivo detection of excised lymph nodes.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 2 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I, Prospective, Open-Label, Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Cancer of the the Endometrium Who Are Undergoing Lymph Node Dissection
Study Start Date : November 2015
Actual Primary Completion Date : April 2018
Actual Study Completion Date : April 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Lymphoseek

Arm Intervention/treatment
Experimental: Lymphoseek plus Vital Blue Dye
Lymphoseek plus Vital Blue Dye: Single dose of 50 µg Lymphoseek radiolabeled with 75 MBq Tc 99m injected pre-operatively followed by next day intra-operative administration of vital blue dye.
Drug: Lymphoseek plus Vital Blue Dye
intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
Other Names:
  • Technetium TC 99M
  • Tilmanocept
  • Lymphazurin




Primary Outcome Measures :
  1. Adverse Events [ Time Frame: 0-15 days Postoperatively ]
    Adverse events experienced by the participants and radiation absorbed dose of injected Lymphoseek.


Secondary Outcome Measures :
  1. Number of Lymphoseek positive lymph nodes detected preoperatively and intraoperatively. [ Time Frame: 2 days ]
    Determination of the number of lymph nodes detected with Lymphoseek by preoperative whole body scan and SPECT/CT imaging and by intraoperative laparoscopic hand held gamma detection device

  2. Number of lymph nodes identified intraoperatively as assessed by visualization and handheld gamma probe detection [ Time Frame: 2 days ]
    Concordance of intraoperative detection rates of Lymphoseek and vital blue dye in histological evaluation and ultrastaging of resected lymph nodes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The patient has provided written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization.
  2. The patient has diagnosed cancer of the endometrium.
  3. The patient is a candidate for surgical intervention, with lymph node dissection being a part of the surgical plan.
  4. The patient is at least 18 years of age at the time of consent.
  5. The patient has an Eastern Cooperative Group (ECOG) performance status of Grade 0 - 2.
  6. The patient has a clinical negative node status at the time of study entry (i.e., Tis-4, N0, M0).
  7. If of childbearing potential, the patient has a negative pregnancy test within 72 hours before administration of Lymphoseek, has been surgically sterilized, or has been postmenopausal for at least 1 year.

Exclusion Criteria:

  1. The patient is pregnant or lactating.
  2. The patient has clinical or radiological evidence of metastatic cancer including palpably abnormal or enlarged lymph nodes (i.e., all patients should be any T, N0, M0).
  3. The patient has a known hypersensitivity to Lymphazurin or Lymphoseek.
  4. The patient has participated in another investigational drug study within 30 days of scheduled surgery.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02589366


Locations
United States, California
University of California, San Diego Moores Cancer Center
La Jolla, California, United States, 92093
Sponsors and Collaborators
University of California, San Diego
Cardinal Health 414, LLC
Investigators
Principal Investigator: Michael McHale, MD, FACS University of California, San Diego

Responsible Party: Michael McHale, Associate Physician Diplomate, University of California, San Diego
ClinicalTrials.gov Identifier: NCT02589366     History of Changes
Other Study ID Numbers: HRPP #141163
First Posted: October 28, 2015    Key Record Dates
Last Update Posted: October 15, 2018
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Michael McHale, University of California, San Diego:
Lymphoseek
endometrial cancer
sentinel lymph node
lymph node dissection

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Diseases
Genital Diseases, Female
Dextrans
Technetium Tc 99m Pentetate
Anticoagulants
Plasma Substitutes
Blood Substitutes
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Radiopharmaceuticals